As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > REGULATORY
REGULATORY
- Biosimilar Guidelines Nearing 1st Revision in 10 Years, MHLW Taking Public Comments
July 2, 2019
- JPWA Fears October Price Revision Will “Set Back” Efforts to Improve Distribution Practices, Asks Govt for Support
July 1, 2019
- Eylea Gets Orphan Status for Neovascular Glaucoma
July 1, 2019
- MHLW Data Show Big Improvement in Single-Product, Single-Price Transaction Rates
July 1, 2019
- Feburic Label to Be Revised due to CV Risk, but No Patient Restrictions to Be Required “at Present”
June 28, 2019
- PMD Amendment Bill Put under Continued Diet Review
June 28, 2019
- Chuikyo Reps Give Kudos to Formulary Initiatives, but Wary on Creating Medical Fees
June 27, 2019
- Chuikyo Raises No Objection to Earlier Price Cuts for LLPs, Payers Want Stricter Rule
June 27, 2019
- MHLW to Conduct Drug Price Survey before October Tax Hike: Chuikyo
June 27, 2019
- No Established Definition Is in Place for Formulary: Govt
June 27, 2019
- Janssen’s HIV Drug Symtuza to Join NHI Price List on July 3
June 27, 2019
- AMED Beats Target with Out-Licensing of 162 Drug Candidates in FY2015-FY2018
June 27, 2019
- Set Lower Premiums for Super Pricey Cell, Gene Therapies: Drug Pricing Organization
June 26, 2019
- Drug Pricing Organization Pitches Earlier Price Cuts for LLPs If AGs Launched, PMP Tweaks and More
June 26, 2019
- AMED to Fund Biomarker Development for Anti-PD-1 Antibodies
June 25, 2019
- Japan Cabinet Adopts 2019 Honebuto Policy, No Big Change Made on Drug Pricing
June 24, 2019
- Govt Earmarks 3 Billion Yen for AMED's Organ-on-Chip Project
June 21, 2019
- ICH to Discuss Use of RWD in Post-Marketing Safety Measures: Amsterdam Meeting
June 20, 2019
- MOF Panel Paper Reiterates Copay Raise for “Small-Risk” Disease Treatments
June 20, 2019
- MHLW Orders Label Revisions for Metformin, Blanket Contraindication for Patients with Severe Kidney Impairment
June 19, 2019
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…